Barclays Appoints Connie Chiang as a Managing Director in Biotech Investment Banking

NEW YORK--(BUSINESS WIRE)--Barclays announces the appointment of Connie Chiang as a Managing Director in Biotech Investment Banking. Ms. Chiang will be based in New York, and will report to Rick Landgarten, Global Head of Healthcare & Real Estate Groups at Barclays.

Ms. Chiang rejoins Barclays from Credit Suisse, where she was a Managing Director and Head of Small/Mid-Cap Biotechnology within Healthcare Investment Banking. Before joining Credit Suisse in 2016, Ms. Chiang spent three years at Barclays as a Director in Healthcare Investment Banking. Ms. Chiang started her career in 2004 in the Healthcare Investment Banking team at Jefferies LLC. Notable transactions that Ms. Chiang has advised on include the $1.2bn sale of Syntimmune to Alexion, PTC Therapeutics' $365mm concurrent convertible and equity offering, Forma Therapeutics’ $319mm IPO, Ra Pharmaceuticals’ $105mm IPO and $58mm follow-on offering, and Mallinckrodt’s $5.6bn acquisition of Questcor.

“We are delighted to welcome Connie back to Barclays and to our Healthcare team. Her deep industry relationships, together with her extensive transactional experience and capabilities, will generate tremendous value for our clients,” said Rick Landgarten, Global Head of Healthcare & Real Estate Groups at Barclays. “Connie’s appointment is further evidence of our significant investment of resources in our life sciences franchise, and our firm commitment to building a market leading business.”

“Barclays is dedicated to investing in top talent to enable us to continue to deliver a superior value proposition for our clients, and this is perfectly demonstrated in Connie’s appointment,” added John Miller, Global Head of Banking Coverage at Barclays. “The Biotech space represents a critical opportunity-set for our investment banking business, and Connie’s addition to the team will ensure that we continue to build on the strong momentum in our broader Healthcare franchise.”

Ms. Chiang will start at Barclays later this month.

Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Group. For further information about Barclays, please visit our website www.barclays.com. Barclays offers investment banking products and services in the US through Barclays Capital Inc.